Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene

Jason R. Navari, Philip Y. Roland, Pacita Keh, Helga B. Salvesen, Lars A. Akslen, Ole E. Iversen, Soma Das, Rajul Kothari, Susan Howey, Benette Phillips

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Normal endometrium, an estrogen-responsive tissue, expresses the estrogen receptor (ER) α gene. Loss of ER expression, the basis for which is currently unknown, is often seen in advanced stage, poor prognosis endometrial tumors. The ER gene undergoes de novo methylation with high frequency in a wide variety of human tumors, including ER-negative breast cancers. In this study, we used several bisulfite-based detection methods to assess whether loss of ER positivity in endometrial tumors is associated with aberrant methylation of the ER gene. Although extensive methylation of a 600-bp region at the 5' end of the gene was seen in two endometrial carcinoma cell lines, none of the 55 CpGs in this region was methylated in 25 of 26 ER-deficient endometrial carcinomas.

Original languageEnglish (US)
Pages (from-to)4026-4032
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number10
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene'. Together they form a unique fingerprint.

Cite this